Press Releases

 
Pulmatrix Reports Q3 2018 Results

LEXINGTON, Mass., Nov. 14, 2018 /PRNewswire/ -- Pulmatrix, Inc. (NASDAQ: PULM) today reported its third quarter results.

Pulmatrix logo (PRNewsFoto/Pulmatrix, Inc.)

"We remain focused on advancing the clinical development of our Pulmazole program," said Robert W. Clarke, Ph.D., chief executive officer of Pulmatrix. "We are pleased with the progress made in preparing for the upcoming Pulmazole clinical trial and plan to initiate the Phase 2 clinical trial of Pulmazole in patients with asthma and ABPA next month."

Financials

As of September 30, 2018, Pulmatrix had $3.8 million in cash and cash equivalents, compared to $3.6 million as of December 31, 2017. 

Research and development expenses for the third quarter of 2018 were $3.1 million, compared to $2.6 million for the same period last year. The increase was primarily due to increases in clinical development costs and external service costs on the Pulmazole program. General and administrative expenses for the third quarter of 2018 were $1.8 million, compared to $2.0 million for the same period last year.

Net loss for the third quarter of 2018 was $4.8 million compared to a net loss of $4.5 million in the same period last year. The increase in net loss was primarily attributable to the noted increases in expenses relating to the Pulmazole program.

About Pulmatrix          
Pulmatrix is a clinical stage biopharmaceutical company developing innovative inhaled therapies to address serious pulmonary disease using its patented iSPERSE™ technology. The Company's proprietary product pipeline is focused on advancing treatments for serious lung diseases, including Pulmazole, an inhaled anti-fungal for patients with allergic bronchopulmonary aspergillosis ("ABPA"), and PUR1800, a narrow spectrum kinase inhibitor for patients with obstructive lung diseases including asthma and chronic obstructive pulmonary disease ("COPD"). Pulmatrix's product candidates are based on iSPERSE™, its proprietary engineered dry powder delivery platform, which seeks to improve therapeutic delivery to the lungs by maximizing local concentrations and reducing systemic side effects to improve patient outcomes.

FORWARD-LOOKING STATEMENTS
Certain statements in this press release that are forward-looking and not statements of historical fact are forward-looking statements within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. The Company cautions that such statements involve risks and uncertainties that may materially affect the Company's results of operations. Such forward-looking statements are based on the beliefs of management as well as assumptions made by and information currently available to management. Actual results could differ materially from those contemplated by the forward-looking statements as a result of certain factors, including but not limited to the ability to establish that potential products are efficacious or safe in preclinical or clinical trials; the ability to establish or maintain collaborations on the development of therapeutic candidates; the ability to obtain appropriate or necessary governmental approvals to market potential products; the ability to obtain future funding for developmental products and working capital and to obtain such funding on commercially reasonable terms; the Company's ability to manufacture product candidates on a commercial scale or in collaborations with third parties; changes in the size and nature of competitors; the ability to retain key executives and scientists; and the ability to secure and enforce legal rights related to the Company's products, including patent protection. A discussion of these and other factors, including risks and uncertainties with respect to the Company, is set forth in the Company's filings with the Securities and Exchange Commission, including its annual report on Form 10-K filed by the Company with the Securities and Exchange Commission on March 13, 2018, as may be supplemented or amended by the Company's Quarterly Reports on Form 10-Q. The Company disclaims any intention or obligation to revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.

 

Financial Tables to Follow

 

CONDENSED CONSOLIDATED BALANCE SHEETS
(in thousands, except share and per share data)







At September 30,
2018

At December 31,
2017



(unaudited)



Assets




Current assets:




Cash and cash equivalents

$                 3,806

$                3,550


Prepaid expenses and other current assets

914

696






Total current assets

4,720

4,246


Property and equipment, net

447

614


Long-term restricted cash

204

204


Goodwill

10,914

10,914






Total assets

$               16,285

$              15,978






Liabilities and stockholders' equity




Current liabilities:




Loan payable, net of debt discount and issuance costs

$                       —

$                3,221


Accounts payable

1,367

457


Accrued expenses

2,284

2,162


Derivative liability

1






Total current liabilities

3,651

5,841






Stockholders' equity:




Common stock, $0.0001 par value — 200,000,000 shares authorized; 46,927,221 and 21,047,498 shares issued and outstanding at September 30, 2018 and December 31, 2017, respectively

5

2


Additional paid-in capital

202,856

184,137


Accumulated deficit

(190,227)

(174,002 )






Total stockholders' equity

12,634

10,137






Total liabilities, redeemable convertible preferred stock and stockholders' equity

$               16,285

$              15,978






 


 

 

CONDENSED CONSOLIDATED RESULTS OF OPERATIONS
(unaudited)
(in thousands, except share and per share data)





For the Three Months Ended
September 30,


2018

2017

Revenues

$                     —

$                335

Operating expenses



Research and development

3,056

2,618

General and administrative

1,769

2,021




Total operating expenses

4.825

4,639




Loss from operations

(4,825)

(4,304)

Interest expense

(153)

Other income, net

9

5




Net loss

$            (4,816)

$           (4,452)




Net loss per share attributable to common stockholders, basic and diluted

$              (0.10)

$             (0.22)




Weighted average shares used to compute basic and diluted net loss per share attributable to common stockholders

46,927,221

20,200,893







 

Investor Contact


Robert Clarke, CEO

William Duke, CFO

(781) 357-2333 

(781) 357-2333

rclarke@pulmatrix.com

wduke@pulmatrix.com

 

SOURCE Pulmatrix, Inc.


print email rss
 
 
© 2015 Pulmatrix, Inc. All Rights Reservedhome   about pulmatrix   platform   pipeline   investors   careers   contact   site design